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cervical cancer, and death) was developed. Thirty cervical screening strategies were 
investigated, including the American College of Obstetricians and Gynecologists’ 
recommendation: screening women every 2 years starting at age 21 years, increasing 
to 3 years following three consecutive negative tests after age 29 (denoted “21/2–3”). 
Other strategies varied initial screening age (16, 21, or 25 years) and screening fre-
quency before and after age 30 years (every 1, 2, 3, 4, or 5 years). Vaccination was 
assumed to provide 95% efﬁ cacy against CIN2+ due to types 16/18 and 37.4% efﬁ -
cacy against CIN2+ excluding co-infections due to HPV types 16/18 (extrapolated to 
efﬁ cacy against infection). The primary outcome was incremental cost-effectiveness 
ratio (ICER) per quality-adjusted life-year (QALY) gained. Full screening compliance 
and vaccination coverage were assumed; all outcomes discounted at 3% per year. 
RESULTS: The 25/5–5NV strategy (every 5 years starting at age 25 years, without 
vaccination) was least costly. No other screening scenario without vaccination was 
cost-effective. The 25/5–5V strategy was cost-effective compared with the 25/5–5NV 
strategy ($9,000/QALY). Other non-dominated strategies (25/3–4V, 25/2–3V, and 
25/1–2V) produced ICERs above $100,000 per QALY. CONCLUSIONS: Model 
results suggest initiating screening at age 25 with a 5-year frequency in the presence 
of HPV vaccination is cost-effective compared with increasing screening frequency 
without vaccination or lowering the age of screening initiation. Increasing HPV vac-
cination in 12-year-old women would allow for less frequent screening initiated at 
older ages, constituting an efﬁ cient use of health care resources.
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OBJECTIVES: Dutasteride and ﬁ nasteride are indicated for treatment of BPH and 
both agents have demonstrated efﬁ cacy as risk reduction (RR) of PCa. The present 
work assesses the cost-effectiveness of the combined effect of each drug on BPH 
progression and RR of PCa, in the treatment of BPH patients with a risk of developing 
prostate cancer (PSA ≥ 3). METHODS: A previously validated Markov model was 
populated to simulate the cost-effectiveness of treatment with dutasteride or ﬁ nasteride 
in men with BPH and a PSA-level ≥3. Equal effect was assumed of the two drugs on 
BPH progression, and an indirect comparison was performed to compare RR effect on 
PCa for dutasteride (the REDUCE trial) and ﬁ nasteride (the PCPT trial). Due to different 
study design and populations in the two trials, an adjustment was made to the REDUCE 
trial results to match the PCPT trial design. Data on incidence, costs and quality-of-life 
for BPH and PCa were retrieved from registries, publications and expert opinions. The 
outcome is presented as incremental cost per QALY and results were presented in c2009. 
Extensive sensitivity analyses were performed to present the uncertainties in the results. 
RESULTS: Estimated RRR of clinically detectable PCa in REDUCE was 33.3%–73%, 
depending risk level chosen as trigger for detection of PCa, compared to 19% for 
ﬁ nasteride. Incremental cost per QALY gained was estimated at c28,970 with the most 
conservative risk reduction of 33%. Sensitivity analysis gave a range from c4,940 to 
c54,200 per QALY. Results were most sensitive to changes in level of risk-reducing 
beneﬁ t of PCa and quality-of-life weights attributed to the diagnosis of PCa. CON-
CLUSIONS: Use of dutasteride to reduce the risk of PCa and BPH progress is expected 
to be cost-effective compared to ﬁ nasteride when used in 60-year-old men with BPH 
and PSA ≥ 3.
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INDIRECT COSTS OF PREGNANCY, PARTURITION AND PUERPERIUM 
IN POLAND
Szkolut S1, Jakubczyk M1, Hermanowski T2
1Medical University of Warsaw, Warsaw, Poland; 2Department of Pharmacoeconomics, 
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: The aim was to estimate the indirect costs of absenteeism generated 
by women during pregnancy and in post-natal period. The secondary objective was 
to quantify the indirect costs in relation to the maternity beneﬁ ts and examine the 
shares of absenteeism caused by pregnancy, childbirth, and puerperium in a total 
disease-related absenteeism in Poland. METHODS: The indirect costs of pregnancy 
were estimated using human capital approach. Social Insurance Ofﬁ ce reports on the 
disease-related absenteeism in Poland in the years 2006–2008 were used as a data 
source. The sickness beneﬁ ts (equal to wages) were used to estimate the indirect costs 
of monthly absence. Indirect costs were compared with the forecasted production 
value to be generated by a child in a life-time horizon (discounted with a rate of 5%, 
accounting for survival probabilities, changing wages and rate of activity rate). 
RESULTS: The pregnancy, parturition and puerperium related absenteeism repre-
sented in years 2006–2008 successively 15.1%, 15.8% and 16.7% of the total disease-
related absenteeism in Poland. The cost of absenteeism during pregnancy, childbirth 
and puerperium in 2006 amounted to c242 million (1c = approx. 4.10 PLN), and in 
2 successive years increased by an average of c66 million yearly. Indirect cost associ-
ated with maternity leaves in years 2006–2008 amounted to c267.7 million, c341.8 
million, and c441.6 million respectively. The total indirect costs of pregnancy in years 
2006–2008 achieved an average of c651.1 million. The indirect cost related with single 
pregnancy was estimated at c1650 representing only 3.5% of future estimated produc-
tion value generated by a child (c47,083). CONCLUSIONS: However pregnancy is 
obviously not an illness, the indirect costs thereof can be calculated and should be 
used when evaluating the impact of family-friendly policies. The indirect costs are 
negligible comparing to future beneﬁ ts.
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OBJECTIVES: The work absenteeism due to care for a sick person can be considered 
as indirect costs of illness. This study aimed at assessing the global burden of caring 
for the ill on productivity in Poland. METHODS: Data were obtained from a survey 
that incorporated information on a burden of caring for the sick and the WPAI-GH 
questionnaire during computer-assisted personal interview in a representative sample 
of the Polish general population aged more than 15 years. There were 2019 respon-
dents, gathered in two waves in January and May 2010. Human capital approach was 
used with GDP per capita as a measure for the monetary value of a time unit (c4.2 
per hour). RESULTS: The ﬁ nal population comprised 795 employees among whom 
167 respondents (21%) took care for a sick person in the last 12 months—78 (10%), 
74 (9%), and 19 (2%) responders took care for a child, other family member and 
non-family member, respectively. On average a respondent spent 9 hours a day (h/d) 
taking care of a sick person for an average period of 21 days (11 h/d for 14 d caring 
for a child; 7 h/d for 23 d caring for other family member; 13 h/d for 22 d caring for 
non-family member). These 9 hours were reduced working time (3,4 h) and off-work 
activities (5.6 h). Estimated productivity lost equals c303 on average per year for 
individuals looking after the ill and c11 on average per year for each employee. 
CONCLUSIONS: Caring for the sick, mostly family members, inﬂ uences working 
time of Polish employees. Productivity loss of a single employee has a moderate impact 
on production, but in global scale or in speciﬁ c health condition it might be perceived 
as an important factor modifying indirect costs of illness.
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OBJECTIVES: The assessment of individuals’ demand and related costs can guide to 
allocate health care resources and improve access to health care. We created a seg-
mentation demand model and we estimated health care costs and their determinants 
within speciﬁ c and distinguished groups of general population. METHODS: The 
target population included subjects living in an area of northern Italy registered at one 
Local Healthcare Unit in 2005 (1,031,684 subjects). On the basis of clinical judgments 
and literature, we identiﬁ ed eight different segments: subjects unknown to HS, mater-
nity and infancy, elderly, people with one chronic disease (CD), people with more 
CDs, people with probable or not severe CDs, subjects with acute event, healthy 
people. To describe these groups and their health demand, we used demographic and 
health care demand data (hospital admissions, drug’s prescriptions, medical specialist 
visits, diagnostic tests) from administrative databases available at the Lombardy 
Health System (HS). These were merged adopting probabilistic record linkage 
(DENALI Data Warehouse) to optimize correct matching of data. RESULTS: Overall, 
health care cost c834 million in 2005 (c809 per-capita). Healthy people were 53% of 
the sample and cost c180 per-capita. Next more frequent subjects were those with 
one CD (14%) and cost c916 per-capita, then those with more CDs (13%) who cost 
c3457 per-capita. Hospitalizations were the cost driver in 5 segments (maternity and 
infancy, elderly, one CD, more CDs, acute event), accounting for 42–89% of total 
costs. Diagnostic tests and medical visits contributed to 42–45% of total costs among 
healthy subjects and those with probable CD. Drugs accounted for 24% of costs of 
sample. CONCLUSIONS: This pioneer demand segmentation model shows an 
example of how merging different administrative databases makes possible under-
standing effects of their characteristics on health care demand and costs. Research is 
encouraged to improve model and study speciﬁ c variants that can be applied in dif-
ferent health care contexts. 
INDIVIDUAL’S HEALTH – Patient-Reported Outcomes Studies
PIH27
ADHERENCE TO PRESCRIPTION MEDICATIONS IS HIGHER WITH USE 
OF A GENERAL PRACTITIONER
Goren A1, DiBonaventura M1, Gupta S2, Wagner JS1, Freedman D2
1Kantar Health, New York, NY, USA; 2Kantar Health, Princeton, NJ, USA
OBJECTIVES: Non-adherence to treatment regimens results in risks and health care 
costs due to increased emergency care. One reason for non-adherence, especially with 
multiple prescriptions, may be the lack of coordination of care among multiple special-
ists (Cutler & Everett, 2010). Assuming that general/family practitioners (GPs) help 
coordinate patient care, the current study examined the impact on adherence of visit-
ing a GP. METHODS: Adherence data from the European 2008 National Health and 
Wellness Survey (a self-reported online survey sampling respondents from the UK, 
France, Germany, Italy, and Spain) were analyzed, with ANOVAs or negative bino-
mial regressions (for resource utilization), as a function of seeing a GP (yes/no) crossed 
with number of prescriptions (1–2, 3–4, and 5+). Adherence, the main outcome, was 
a Morisky Score ranging from 0 (perfect adherence) to 4 (low adherence). Health 
care resource utilization measures included number of hospitalizations and visits to 
the emergency room (ER) in the past six months. RESULTS: There were 17,690 
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respondents (of 53,524 total) using 1–2 (n = 6,434), 3–4 (5,529), or 5+ (5,727) pre-
scription medications for symptomatic conditions. Adherence was higher among those 
who saw a GP in the past 6 months (M = 1.19, SD = 1.24, n = 14,802) vs. those who 
did not (M = 1.36, SD = 1.29, n = 2,888), P < 0.001, and higher among those with 
a higher number of prescriptions (for 5+, 3–4, and 1–2: Ms = 0.99, 1.26, and 1.38; 
SDs = 1.18, 1.26, and 1.27, respectively), P < 0.001. Hospitalizations were lower 
among GP visitors (M = 0.30, SD = 2.39) than non-visitors (M = 0.34, SD = 2.07), P 
< 0.001, ER visits were lower among GP visitors (M = 0.32, SD = 1.20) than non-
visitors (M = 0.33, SD = 2.09), P < 0.001, and both were signiﬁ cantly higher among 
those with more prescriptions, ps < 0.001. The beneﬁ ts of a GP were largely indepen-
dent of number of medications. CONCLUSIONS: Among European patients taking 
prescriptions, visiting a GP was associated with greater adherence and lower health 
care resource utilization.
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OBJECTIVES: The aim of this study is to answer the following questions: 1) How 
high is the self-reported nonadherence (NA) of German patients with the need to regu-
larly take medication? and 2) Which factors capable of explaining this self-reported 
NA can be identiﬁ ed by multivariate analysis? METHODS: Two cross-sectional 
surveys (phone survey with 1177 patients; face-to-face in-depth survey with 340 
patients in 17 German pharmacies) were conducted. Self-reported NA was measured 
by the generic Morisky scale (either as 4 items or 8 item MMAS). Identiﬁ cation of 
explanatory factors was conducted on the basis of multivariate logistic regression 
analysis (including the calculation of additive risks by dichotomization of signiﬁ cant 
explanatory factors). RESULTS: 1) Approximately 35–40 % of the patients can be 
described as non-adherent (38.8 %/35.3 %); 2a) Survey 1: Only a few socio-demo-
graphic factors are able to explain the NA (chronic disease, some aspects of age, and 
low number of required medications to take); and 2b) Survey 2: Most results of the 
ﬁ rst survey can be replicated. However, intentional NA explanations have consider-
ably more inﬂ uence: positive medication belief, a positive mood, and a good patient-
doctor relationship reduce the NA risk. Furthermore, patients who are easily able to 
recognize the correct medication on the basis of the identiﬁ cation of the packaging 
have a signiﬁ cantly reduced NA probability. When additive risk is considered, patients 
who are chronically ill but display no other risk factors have an NA probability rate 
of 10.4 %, for patients displaying all identiﬁ ed risk factors this rate increases to 93.9 
%. CONCLUSIONS: Our surveys are the largest and most detailed to have been 
conducted in Germany concerned with the theme of medication-based NA. Our results 
show that approximately one-third of patients can be classiﬁ ed as non-adherent. 
Intentional NA factors explain the NA considerably better than do socio-economic 
factors.
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OBJECTIVES: A regional health plan implemented a specialty pharmacy beneﬁ t with 
increased copayment/coinsurance for specialty medications. Our objective was to 
measure and compare the change in adherence and persistence after implementation 
of the specialty beneﬁ t. METHODS: Pharmacy claims for patients who chronically 
used anti-inﬂ ammatory, immunosuppressant, cancer, and multiple sclerosis medica-
tions were assessed. The intervention group consisted of those whose out-of-pocket 
cost-share for specialty medications increased by at least $25 (per 30-day ﬁ ll), and the 
control group consisted of those whose out-of-pocket amounts did not change. Adher-
ence, deﬁ ned by proportion of days covered (PDC), was measured every 3 months for 
12 months before and after the copay change. Paired t-tests compared the adherence 
in the pre- vs. post-periods. Individual growth model analysis evaluated the changes 
in adherence throughout the time periods. Cox regression analysis determined the 
difference in persistence between groups after the copay change, controlling for age, 
gender, copay level, group, and pre-period persistence. RESULTS: There were 237 
patients in the intervention group and 211 patients in the control group. The PDC 
results varied by drug type; adherence decreased after the copay change in the interven-
tion group for patients on anti-inﬂ ammatory, immunosuppressant, and multiple scle-
rosis medications, but remained consistent for patients on antineoplastics. The growth 
model showed a small, but statistically signiﬁ cant decrease in PDC of 0.01 after copay 
changes (P = 0.014). The Cox regression analysis indicated that the estimated risk of 
discontinuing therapy increased for patients in the intervention vs. control groups 
(hazard ratio = 2.35, 95% CI: 1.43–3.58). CONCLUSIONS: The move to the specialty 
pharmacy beneﬁ t allows for closer scrutiny of specialty utilization by pharmacists who 
actively monitor utilization and access. Despite the minimal adherence decrease and 
signiﬁ cant persistence changes, the results indicated relatively more stability with the 
use of specialty medications than that reported with copayment/coinsurance increases 
for traditional pharmaceutics.
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OBJECTIVES: Women with PMO are most often treated with bisphosphonates (BPs), 
as well as with strontium ranelate (SR) and raloxifene (RLX). However, a high per-
centage of patients are not persistent after 1 year of therapy, which can compromise 
treatment effectiveness (Imaz I, Osteoporos Int 2010) and thus increase the risk of 
fractures. The objective was to estimate the persistence to PMO treatments in a region 
of Spain (Catalonia) representative of the Spanish population. METHODS: This 
database analysis included women with PMO from 6 primary care centers, aged ≥50 
years who initiated BPs (alendronate, ibandronate, risedronate), SR or RLX between 
January 1, 2004 and June 30, 2008. Patients with cancer, other bone diseases, hospi-
talization >30 days or <1 year follow-up data were excluded. Persistence was measured 
at 1, 2 or 3 years according to prescriptions dispensed at ofﬁ ce-based pharmacies. 
Three patients’ cohorts were analyzed: patients with ≥1 year (cohort 1), ≥2 years 
(cohort 2) and ≥3 years (cohort 3) follow-up. Patients with no access to medication 
for >1 month were considered non-persistent and a switch to another PMO treatment 
was considered a discontinuation. In a secondary analysis, switch was not considered 
a discontinuation. Statistics were performed using Kaplan-Meier methodology. 
RESULTS: A total of 3,049 patients (mean age ± SD; 68.3 ± 9.7 years) were included 
in cohort 1; 30% were persistent after 1 year (95%CI:27.5–32.5). In cohort 2 (n = 
2698; 68.9 ± 9.3 years) persistence was 35% (CI:32.6–36.2) and 16% (CI:13.6–19.2) 
after 1 and 2 years respectively. In cohort 3 (n = 2163; 68.4 ± 9.5 years) persistence 
was 36% (CI:33.9–37.9), 20% (CI:18.3–21.7) and 9% (CI:5.9–12.1) after 1, 2 and 
3 years, respectively. The results were similar by drug and frequency of administration, 
and also when switch was not considered a discontinuation. CONCLUSIONS: In this 
Spanish population of postmenopausal women with osteoporosis, persistence to treat-
ment was poor, even when a switch was not considered a discontinuation.
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OBJECTIVES: Our study focused on revealing difﬁ culties in maintaining balance 
during pregnancy. METHODS: Balance testing was performed on 150 volunteers (50 
healthy pregnant, 50 pathologically pregnant, 50 healthy young non—pregnant 
women). One hundred pregnant women were allocated into 4 subgroups based on 
physical activity performed prior to and during pregnancy. During stabilometer mea-
surements static balance was examined with Romberg test while dynamic balance with 
5 programs on a stabilometer. Statistical data were calculated according to mean, 
standard deviation and T-test while the results were considered to be relevant at P < 
0,05. RESULTS: Average results of Romberg test were worse in groups of pregnant 
women compared to non-pregnant women although the difference was not signiﬁ cant. 
Concerning the subgroups: those who had previously been involved in professional 
sports and were healthy and physically active during pregnancy performed better on 
the open–eye test (P < 0,05) compared to pathologically pregnant patients. Between 
the second and third trimesters of healthy pregnancies no signiﬁ cant results were found 
in Romberg test while a signiﬁ cant difference was detected (P < 0,05) in the perfor-
mance of the 5th exercise of the dynamic balance test. Regarding the 5 programs on 
the stabilometer examining dynamic balance non-pregnant women performed all 
exercises signiﬁ cantly better (P < 0,05) than healthy pregnant women. However when 
compared to pathologically pregnant women apart from the exercises No.2 the result 
showed a signiﬁ cant difference (P < 0,05). Concerning the same exercises healthy 
pregnant women performed signiﬁ cantly better (P < 0,05) in exercises No.1 and No.4. 
Pregnant women who had previously been and remained physically active during 
pregnancy performed the exercise of moving the centre of body weight in a signiﬁ -
cantly shorter time than those who were inactive and hospitalised. CONCLUSIONS: 
Statistical analysis of data proves that physical activity (especially professional sports) 
prior to becoming pregnant and physical activity during pregnancy have positive 
effects.
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OBJECTIVES: Treatments to prevent prostate cancer are associated with side effects 
and the impact of these on health related quality of life (HRQL) should be considered 
in any assessment of cost-effectiveness. However our systematic review identiﬁ ed a 
lack of robust data. a prospective assessment of the impact of side effects was under-
taken using generic and condition-speciﬁ c measures of HRQL. METHODS: Partici-
pants were recruited from an online panel. Men over 55, with either erectile 
dysfunction (ED), loss of libido, gynecomastia or ejaculatory disorders (without other 
chronic disease such as renal failure, diabetes, multiple sclerosis etc), and an age 
matched control group completed assessments of symptom severity and HRQL 
(EQ-5D and Sexual QoL survey—SQoL-3D). Both HRQL measures can provide 
